Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer

被引:54
作者
Diblasio, CJ
Kattan, MW
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, New York, NY 10021 USA
关键词
D O I
10.1016/j.urology.2003.09.029
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The generally indolent nature of prostate cancer, as well as the impact that treatment can have on quality of life (QOL) and cancer control, makes the decision analysis difficult for patients facing the task of selecting a treatment for clinically localized disease. Instruments to aid patients and their physicians in this decision analysis are needed. Nomograms are instruments that predict outcomes using specific clinical parameters. Nomograms use algorithms that incorporate several variables to calculate the predicted probability that a patient will achieve a particular clinical end point. Nomograms tend to outperform both clinical experts and predictive models using methods of risk grouping. We briefly outline the uses and limitations of nomograms, principles of nomogram construction, and the available models for predicting the progression-free probability after local definitive therapy with radical prostatectomy, external-beam radiotherapy, or brachytherapy. There is a need for additional nomograms that predict outcomes after salvage therapy, as well other clinical end points, including QOL-adjusted survival. (C) 2003 Elsevier Inc.
引用
收藏
页码:9 / 18
页数:10
相关论文
共 74 条
[51]   PROGNOSTIC-SIGNIFICANCE OF POSITIVE SURGICAL MARGINS IN RADICAL PROSTATECTOMY SPECIMENS [J].
OHORI, M ;
WHEELER, TM ;
KATTAN, MW ;
GOTO, Y ;
SCARDINO, PT .
JOURNAL OF UROLOGY, 1995, 154 (05) :1818-1824
[52]   Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium [J].
Partin, AW ;
Mangold, LA ;
Lamm, DM ;
Walsh, PC ;
Epstein, JI ;
Pearson, JD .
UROLOGY, 2001, 58 (06) :843-848
[53]   THE USE OF PROSTATE-SPECIFIC ANTIGEN, CLINICAL STAGE AND GLEASON SCORE TO PREDICT PATHOLOGICAL STAGE IN MEN WITH LOCALIZED PROSTATE-CANCER [J].
PARTIN, AW ;
YOO, J ;
CARTER, HB ;
PEARSON, JD ;
CHAN, DW ;
EPSTEIN, JI ;
WALSH, PC .
JOURNAL OF UROLOGY, 1993, 150 (01) :110-114
[54]   Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer - A multi-institutional update [J].
Partin, AW ;
Kattan, MW ;
Subong, ENP ;
Walsh, PC ;
Wojno, KJ ;
Oesterling, JE ;
Scardino, PT ;
Pearson, JD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (18) :1445-1451
[55]  
Perez Carlos A., 2000, Rays (Rome), V25, P331
[56]   Prostate-specific antigen after anatomic radical retropubic prostatectomy - Patterns of recurrence and cancer control [J].
Pound, CR ;
Partin, AW ;
Epstein, JI ;
Walsh, PC .
UROLOGIC CLINICS OF NORTH AMERICA, 1997, 24 (02) :395-&
[57]  
Ragde H, 1997, CANCER, V80, P442, DOI 10.1002/(SICI)1097-0142(19970801)80:3<442::AID-CNCR12>3.0.CO
[58]  
2-X
[59]  
Ragde H, 2000, CANCER, V89, P135, DOI 10.1002/1097-0142(20000701)89:1<135::AID-CNCR18>3.0.CO
[60]  
2-#